A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects
Latest Information Update: 17 Apr 2024
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Acronyms Patiromer JADE
- Sponsors Vifor Fresenius Medical Care Renal Pharma
- 12 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Nov 2026.
- 12 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Oct 2026.
- 25 Mar 2022 Planned End Date changed from 1 Sep 2023 to 1 Mar 2024.